Literature DB >> 1165627

[Insulin and proinsulin secretion under contraceptive steroid administration (author's transl)].

L Hausmann, K M Goebel, D Klähn, H Kaffarnik.   

Abstract

An ivestigation has been performed in 49 women about the influence exerted on the glucose-tolerance, insulin and proinsulin secretion by hormonal contraceptives of different types and compositions. A disturbed dynamics of the insulin secretion with elevated values in the OGTT at two and three hours has been proven at a nearly equal degree using combined preparations (Anacyclin, Eugynon, Neogynon, Mikrogynon) or sequential preparations (Kombiquens, Ovanon). Though there has been interference with the glucose tolerance, the serum proinsulin in the OGTT showed increased levels too. When a combined preparation was applied, the proinsulin values were significantyl higher compared to a sequential type contraceptive. The observed disturbance of the insulin and proinsulin secretion is explained by a decreased sensitivity to insulin in the peripheral fat tissue. The actual dose of the estrogen-gestagen components has no influence on the described changes. Elevated insulin levels are demonstrable already during the first treatment cycle. The degree of the disturbance is independent of the duration of the medicamentous application during the first 6 contraceptive months. After withdrawal of the respective contraceptive steroid the insulin secretion showed nearly normal dynamics during the subseqeunt menstrual cycle.

Entities:  

Keywords:  Biology; Carbohydrate Metabolic Effects; Clinical Research; Contraception; Contraceptive Methods--side effects; Family Planning; Glucose Metabolism Effects; Metabolic Effects; Oral Contraceptives, Combined--side effects; Oral Contraceptives, Phasic; Oral Contraceptives--side effects; Physiology; Research Methodology

Mesh:

Substances:

Year:  1975        PMID: 1165627     DOI: 10.1007/bf01466958

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  33 in total

1.  GLUCOSE TOLERANCE IN WOMEN RECEIVING AN OVULATORY SUPPRESSANT.

Authors:  H GERSHBERG; Z JAVIER; M HULSE
Journal:  Diabetes       Date:  1964 Jul-Aug       Impact factor: 9.461

2.  [Effect of hormone contraceptives, of various compositions, on insulin secretion and carbohydrate tolerance].

Authors:  L Hausmann; J Groll; H Kaffarnik
Journal:  Verh Dtsch Ges Inn Med       Date:  1974

3.  Glucose, insulin, and growth hormone studies in long-term users of oral contraceptives.

Authors:  W N Spellacy; W C Buhi; C E Spellacy; L E Moses; J W Goldzieher
Journal:  Am J Obstet Gynecol       Date:  1970-01-15       Impact factor: 8.661

4.  Serum insulin and intravenous glucose tolerance in oral contraception.

Authors:  J Starup; J Date; T Deckert
Journal:  Acta Endocrinol (Copenh)       Date:  1968-07

5.  Direct measurement of plasma proinsulin in normal and diabetic subjects.

Authors:  W C Duckworth; A E Kitabchi
Journal:  Am J Med       Date:  1972-10       Impact factor: 4.965

6.  Comparison of the mechanisms underlying carbohydrate intolerance in subclinical diabetic women during pregnancy and during post-partum oral contraceptive steroid treatment.

Authors:  P Beck; S A Wells
Journal:  J Clin Endocrinol Metab       Date:  1969-06       Impact factor: 5.958

7.  Purification and characterization of a protease with specificity for insulin from rat muscle.

Authors:  J S Brush
Journal:  Diabetes       Date:  1971-03       Impact factor: 9.461

8.  [Influence of contraceptives on the carbohydrate metabolism in female diabetics].

Authors:  K Mendner
Journal:  Med Welt       Date:  1971-05-15

9.  Estriol modification of the effects of progesterone and human chorionic somatomammotropin on glucose tolerance and plasma insulin in rhesus monkeys.

Authors:  P Beck; D L Hoff
Journal:  Diabetes       Date:  1971-05       Impact factor: 9.461

10.  [Basal and reactive proinsulin and insulin secretion in overweight women (author's transl)].

Authors:  L Hausmann; D Klähn; J Klimek; H Kaffarnik
Journal:  Dtsch Med Wochenschr       Date:  1975-02-14       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.